题名

降血糖藥物鈉－葡萄糖共同輸送器－2抑制劑對心血管疾病的影響

DOI

10.6666/ClinMed.2017.79.4.042

作者

李俊志；陳涵栩

关键词

糖尿病 ； 降血糖藥物 ； 鈉-葡萄糖共同輸送器-2抑制劑 ； 心血管疾病

期刊名称

臨床醫學月刊

卷期/出版年月

79卷4期（2017 / 04 / 28）

页次

228 - 232

内容语文

繁體中文
中文摘要

鈉-葡萄糖共同輸送器-2抑制劑(sodium- glucose cotransporter 2 inhibitors, SGLT-2 抑制劑)是最近幾年來較新的降血糖藥物，其作用機轉主要藉由抑制腎臟近曲小管的SGLT-2，減少尿糖的再吸收，來達到降低血糖的效果。此外SGLT-2抑制劑對於血壓及體重的控制也有些許的幫助。目前較常見使用中的SGLT-2抑制劑包括canagliflozin、dapagliflozin以及empagliflozin，這些藥物目前都有針對心血管疾病危險性的研究，有些仍在研究階段當中尚未發表，有些則發現了降低心血管疾病危險性的結果，著實讓臨床工作者們相當振奮！不過，SGLT-2 抑制劑仍有其副作用(例如泌尿道及生殖道感染…)，以及臨床使用的侷限性(例如腎功能不佳患者不建議使用等…)，這些都是臨床醫師們在使用SGLT-2抑制劑時，所需考量的部分。第二型糖尿病病大多合併有高血壓及體重過重的問題，而且其得到心血管疾病的機率也較一般人高出許多; SGLT-2抑制劑若能證實其心血管疾病的安全性足夠，相信在未來會是治療第二型糖尿病的主流藥物。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Cherney, DZ,Perkins, BA,Soleymanlou, N(2014).Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.Circulation,129,587-597.
  2. European Medicies Agency(2012).EMA Assessment Report 2012EMA Assessment Report 2012,未出版
  3. European Medicines Agency(2013).EMA Assessment Report 2013EMA Assessment Report 2013,未出版
  4. Hach, T,Gerich, J,Salsali, A(2013).Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials.Diabetes,62,69-LB.
  5. Hardy, E,Ptanszynska, A,de Bruin, TWA(2013).Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy.Diabetologia,947,61.
  6. Holman, RR,Paul, SK,Bethel, MA(2008).year follow up of intensive glucose control in type 2 diabetes.N Engl J Med,359,1577-1589.
  7. Howard, G,OŅLeary, DH,Zaccaro, D(1996).Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study(IRAS) Investigators.Circulation,93,1809-1017.
  8. Huxley, R,Barzi, F,Woodward, M(2006).Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.BMJ,332,73-78.
  9. Inzucchi, SE,Zinman, B,Wanner, C(2015).SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Diab Vasc Dis Res,12,90-100.
  10. Lambers Heerspink, HJ,de Zeeuw, D,Wie, L(2013).Dapagliflozin a glucoseregulating drug with diuretic properties in subjects with type 2 diabetes.Diabetes Obes Metab,15,853-862.
  11. Lee, MJ,Wu, Y,Fried, SK(2013).Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications.Mol Aspects Med,34,1-11.
  12. Merovci, A,Solis-Herrera, C,Daniele, G(2014).DapagliÀozin improves muscle insulin sensitivity but enhances endogenous glucose production.The Journal of Clinical Investigation,124,509-514.
  13. Nagareddy, PR,Murphy,AJ,Stirzaker, RA(2013).Hyperglycaemia promotes myelopoiesis and impairs the resolution of atherosclerosis.Cell Metabolism,17,695-708.
  14. Nauck, MA(2014).Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.Drug Des Devel Ther,8,1335-1380.
  15. Sonesson, C,Johansson, PA,Johnsson, E(2016).Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Cardiovasc Diabetol,15,37.
  16. Standl, E,Schnell, O,Ceriello, A(2011).Postprandial hyperglycemia and glycemic variability: should we care?.Diabetes Care,34,S120-S127.
  17. US Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana(Canagliflozin) tablets 2013.
  18. Vasilakou, D,Karagiannis, T,Athanasiadou, E(2013).Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and metaanalysis.Ann Intern Med,159,262-274.
  19. Zinman, B,Wanner, C,Lachin, JM(2015).EmpagliÀozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med,373,2117-2128.
print cancel